Article Sidebar
Published:
Apr 19, 2023DOI:
10.4314/tjpr.v22i3.7Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Leonurine inhibits breast cancer cell growth and angiogenesis via PI3K/AKT/mTOR pathway
Abstract
Purpose: To elucidate the effect of leonurine on the proliferation, invasion, migration, and angiogenetic potential of breast cancer cells.
Methods: Human breast cancer cell line (MDA-MB-231) and normal breast cell line, (SK-BR-3) were cultured. Both cell lines were treated with 200, 400, or 800 μM leonurine and cultured for 0 (control), 24, 48, or 72 h. Cell counting kit-8 (CCK8) and colony formation assays were performed to measure cell viability and proliferation. Invasion and migration were evaluated using in vitro invasion and wound healing assays, respectively, while angiogenesis was evaluated by the formation of branching point structures. Furthermore, phosphorylation of PI3K, AKT, and mTOR were assessed by Western blot. Cell viability, invasion, migration, and angiogenesis were further investigated in media including 740Y-P, 800 μM leonurine, and 800 μM leonurine plus 740Y-P.
Results: Leonurine inhibited the proliferation of breast cancer cells and weakened breast cancer cell invasion, migration, and angiogenetic potential in a dose-dependent manner (p < 0.05). Furthermore, leonurine repressed PI3K/AKT/mTOR pathway by reducing the phosphorylation of PI3K, AKT, and mTOR. Leonurine also inhibited breast cancer progression (p < 0.05).
Conclusion: Leonurine inhibits breast cancer progression by inhibiting PI3K/AKT/mTOR pathway, and is thus, a potential agent for the management of breast cancer.
